In breast cancer patients, both humoral (Kotera et al, 1994; von Mensdorff-Pouilly et al, 2000; Snijdewint et al, 2001) and cellular (Correa et al, 2005) responses to MUC1 have been documented and a number of clinical studies have been initiated to investigate the use of MUC1-based immunogens in different tumour types (Tang et al, 2008). This evidence concerns the gene MUC1 and breast carcinoma.